Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

FosA3 emerging in clinical carbapenemase-producing C. freundii

V. Mattioni Marchetti, I. Venturelli, T. Cassetti, M. Meschiari, R. Migliavacca, I. Bitar

. 2024 ; 14 (-) : 1447933. [pub] 20240806

Jazyk angličtina Země Švýcarsko

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc24019384

Fosfomycin (FOS) is an effective antibiotic against multidrug-resistant Enterobacterales, but its effectiveness is reducing. Little is known on the current prevalence of FosA enzymes in low-risk pathogens, such as Citrobacter freundii. The aim of the study was the molecular characterization of a carbapenemase- and FosA-producing C. freundii collected in Italy. AK867, collected in 2023, showed an XDR profile, retaining susceptibility only to colistin. AK867 showed a FOS MIC >128 mg/L by ADM. Based on WGS, AK867 belonged to ST116 and owned a wide resistome, including fosA3, blaKPC-2, and blaVIM-1. fosA3 was carried by a conjugative pKPC-CAV1312 plasmid of 320,480 bp, on a novel composite transposon (12,907 bp). FosA3 transposon shared similarities with other fosA3-harboring pKPC-CAV1312 plasmids among Citrobacter spp. We report the first case of FosA3 production in clinical carbapenemase-producing C. freundii ST116. The incidence of FosA3 enzymes is increasing among Enterobacterales, affecting even low-virulence pathogens, as C. freundii.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24019384
003      
CZ-PrNML
005      
20241024110741.0
007      
ta
008      
241015e20240806sz f 000 0|eng||
009      
AR
024    7_
$a 10.3389/fcimb.2024.1447933 $2 doi
035    __
$a (PubMed)39247055
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Mattioni Marchetti, Vittoria $u Microbiology and Clinical Microbiology Unit, Scienze Clinico, Chirurgiche, Diagnostiche, Pediatriche (SCCDP) Department, University of Pavia, Pavia, Italy
245    10
$a FosA3 emerging in clinical carbapenemase-producing C. freundii / $c V. Mattioni Marchetti, I. Venturelli, T. Cassetti, M. Meschiari, R. Migliavacca, I. Bitar
520    9_
$a Fosfomycin (FOS) is an effective antibiotic against multidrug-resistant Enterobacterales, but its effectiveness is reducing. Little is known on the current prevalence of FosA enzymes in low-risk pathogens, such as Citrobacter freundii. The aim of the study was the molecular characterization of a carbapenemase- and FosA-producing C. freundii collected in Italy. AK867, collected in 2023, showed an XDR profile, retaining susceptibility only to colistin. AK867 showed a FOS MIC >128 mg/L by ADM. Based on WGS, AK867 belonged to ST116 and owned a wide resistome, including fosA3, blaKPC-2, and blaVIM-1. fosA3 was carried by a conjugative pKPC-CAV1312 plasmid of 320,480 bp, on a novel composite transposon (12,907 bp). FosA3 transposon shared similarities with other fosA3-harboring pKPC-CAV1312 plasmids among Citrobacter spp. We report the first case of FosA3 production in clinical carbapenemase-producing C. freundii ST116. The incidence of FosA3 enzymes is increasing among Enterobacterales, affecting even low-virulence pathogens, as C. freundii.
650    _2
$a lidé $7 D006801
650    12
$a antibakteriální látky $x farmakologie $7 D000900
650    12
$a bakteriální proteiny $x genetika $x metabolismus $7 D001426
650    12
$a beta-laktamasy $x genetika $x metabolismus $7 D001618
650    12
$a Citrobacter freundii $x genetika $x enzymologie $x účinky léků $7 D016971
650    _2
$a transpozibilní elementy DNA $7 D004251
650    _2
$a mnohočetná bakteriální léková rezistence $x genetika $7 D024901
650    12
$a enterobakteriální infekce $x mikrobiologie $7 D004756
650    12
$a fosfomycin $x farmakologie $7 D005578
650    _2
$a mikrobiální testy citlivosti $7 D008826
650    _2
$a plazmidy $x genetika $7 D010957
650    _2
$a sekvenování celého genomu $7 D000073336
651    _2
$a Itálie $x epidemiologie $7 D007558
655    _2
$a časopisecké články $7 D016428
700    1_
$a Venturelli, Irene $u Clinical Microbiology, Azienda Unità Sanitaria Locale (AUSL) Modena, Modena, Italy
700    1_
$a Cassetti, Tiziana $u Clinical Microbiology, Azienda Unità Sanitaria Locale (AUSL) Modena, Modena, Italy
700    1_
$a Meschiari, Marianna $u Infectious Diseases Clinic, Azienda Ospedaliera Universitaria (AOU) Policlinico di Modena, Modena, Italy
700    1_
$a Migliavacca, Roberta $u Microbiology and Clinical Microbiology Unit, Scienze Clinico, Chirurgiche, Diagnostiche, Pediatriche (SCCDP) Department, University of Pavia, Pavia, Italy $u I.R.C.C.S. Policlinico S. Matteo, Pavia, Italy
700    1_
$a Bitar, Ibrahim $u Department of Microbiology, Faculty of Medicine, University Hospital in Pilsen, Charles University, Pilsen, Czechia $u Biomedical Center, Faculty of Medicine, Charles University, Pilsen, Czechia
773    0_
$w MED00182987 $t Frontiers in cellular and infection microbiology $x 2235-2988 $g Roč. 14 (20240806), s. 1447933
856    41
$u https://pubmed.ncbi.nlm.nih.gov/39247055 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20241015 $b ABA008
991    __
$a 20241024110735 $b ABA008
999    __
$a ok $b bmc $g 2201927 $s 1231357
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2024 $b 14 $c - $d 1447933 $e 20240806 $i 2235-2988 $m Frontiers in cellular and infection microbiology $n Front Cell Infect Microbiol $x MED00182987
LZP    __
$a Pubmed-20241015

Najít záznam

Citační ukazatele

Možnosti archivace